Cencora (NYSE:COR) Price Target Raised to $335.00 at UBS Group

Cencora (NYSE:COR) had its price objective hoisted by UBS Group from $298.00 to $335.00 in a report issued on Tuesday morning,Benzinga reports. UBS Group currently has a buy rating on the stock.

COR has been the topic of a number of other reports. Wells Fargo & Company boosted their target price on Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research report on Friday, March 14th. Morgan Stanley set a $288.00 target price on shares of Cencora in a report on Tuesday, April 15th. StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Evercore ISI lifted their price objective on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Finally, Bank of America upped their target price on shares of Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a research report on Friday, April 11th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and a consensus target price of $289.09.

Cencora Stock Up 0.8 %

NYSE COR opened at $290.12 on Tuesday. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora has a 12 month low of $214.77 and a 12 month high of $296.65. The stock’s 50 day moving average is $269.87 and its 200 day moving average is $250.27. The stock has a market cap of $56.26 billion, a PE ratio of 41.27, a P/E/G ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Research analysts predict that Cencora will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.76%. The ex-dividend date was Friday, February 14th. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the transaction, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Chairman Steven H. Collis sold 14,579 shares of the business’s stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the sale, the chairman now owns 315,913 shares of the company’s stock, valued at $89,027,442.53. The trade was a 4.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,223 shares of company stock worth $13,580,967 over the last quarter. Company insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Cencora

A number of institutional investors and hedge funds have recently bought and sold shares of COR. JFS Wealth Advisors LLC increased its stake in shares of Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after buying an additional 46 shares during the period. Hoey Investments Inc. purchased a new position in Cencora during the 1st quarter valued at about $28,000. Banque Transatlantique SA bought a new stake in shares of Cencora in the 4th quarter valued at about $29,000. SBI Securities Co. Ltd. purchased a new stake in shares of Cencora in the 4th quarter worth approximately $30,000. Finally, Householder Group Estate & Retirement Specialist LLC boosted its stake in shares of Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after purchasing an additional 69 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.